Profile data is unavailable for this security.
About the company
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
- Revenue in EUR (TTM)487.42m
- Net income in EUR97.59m
- Incorporated--
- Employees746.00
- LocationFaes Farma SAAvda. Autonomia 10LEIOA 48940SpainESP
- Phone+34 944818300
- Fax+34 944818301
- Websitehttps://faesfarma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Lukang Pharmaceutical Co Ltd | 802.25m | 52.85m | 1.06bn | 6.48k | 20.18 | 2.06 | -- | 1.32 | 0.443 | 0.443 | 6.83 | 4.33 | 0.6850 | 3.39 | 6.92 | 937,972.80 | 4.66 | 2.21 | 7.60 | 4.05 | 22.74 | 23.41 | 6.80 | 3.46 | 0.8266 | 4.48 | 0.4744 | 31.79 | 9.34 | 13.04 | 78.37 | 8.81 | -16.95 | 23.94 |
| Avadel Pharmaceuticals PLC (ADR) | 131.90m | -69.29m | 1.07bn | 154.00 | -- | 15.04 | -- | 8.12 | -0.7894 | -0.7894 | 1.48 | 0.775 | 0.7647 | 1.04 | 6.38 | 897,142.90 | -40.17 | -40.21 | -54.87 | -47.99 | 91.92 | -- | -52.53 | -374.75 | 2.60 | -6.11 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 280.04m | 20.13m | 1.08bn | 3.37k | 53.71 | 3.03 | -- | 3.86 | 0.7235 | 0.7235 | 10.06 | 12.84 | 0.4823 | 1.00 | 3.71 | 629,969.20 | 3.42 | 7.38 | 4.66 | 9.60 | 44.42 | 47.03 | 7.08 | 13.53 | 1.01 | 4.45 | 0.3229 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Akums Drugs and Pharmaceuticals Ltd | 460.88m | 31.38m | 1.08bn | 7.39k | 33.38 | 3.29 | 22.97 | 2.35 | 18.26 | 18.26 | 272.23 | 185.07 | 1.04 | 3.77 | 3.94 | 5,521,446.00 | 7.20 | -- | 11.08 | -- | 37.76 | -- | 6.95 | -- | 1.59 | 2.23 | 0.1571 | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| FAES Farma SA | 487.42m | 97.59m | 1.09bn | 746.00 | 10.92 | -- | 9.28 | 2.24 | 0.3155 | 0.3155 | 1.58 | -- | -- | -- | -- | 278,843.80 | -- | 13.06 | -- | 15.20 | 66.53 | 64.10 | 19.97 | 19.79 | -- | 1,120.37 | -- | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| ANI Pharmaceuticals Inc | 530.29m | -8.37m | 1.12bn | 642.00 | -- | 2.90 | 22.76 | 2.11 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Kissei Pharmaceutical Co Ltd | 500.82m | 66.29m | 1.12bn | 1.78k | 15.27 | 0.7426 | 11.91 | 2.24 | 241.71 | 241.71 | 1,825.83 | 4,969.03 | 0.3294 | 1.60 | 2.98 | 45,568,860.00 | 4.38 | 3.61 | 4.75 | 3.90 | 49.88 | 49.47 | 13.31 | 12.69 | 4.15 | -- | 0.0057 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
| Tilray Brands Inc | 775.25m | -202.99m | 1.13bn | 2.65k | -- | 0.3297 | -- | 1.46 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Faes Farma SA's reporting currency: Euro EUR
16.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alantra EQMC Asset Management SGIIC SAas of 05 Sep 2024 | 15.85m | 5.01% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 11.00m | 3.48% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 5.00m | 1.58% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 4.52m | 1.43% |
| Fidelity Management & Research Co. LLCas of 31 Aug 2024 | 4.11m | 1.30% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.90m | 0.92% |
| Bankinter Gesti�n de Activos SA SGIICas of 30 Jun 2024 | 2.34m | 0.74% |
| KBC Asset Management NVas of 30 Jun 2024 | 2.18m | 0.69% |
| Santander Asset Management SA SGIICas of 30 Jun 2024 | 2.10m | 0.66% |
| Praude Asset Management Ltd.as of 29 Feb 2024 | 1.39m | 0.44% |
More ▼
Data from 29 Feb 2024 - 08 Nov 2024Source: FactSet Research Systems Inc.
